Marked variability in reported minimal residual disease lower level of detection of 4 hematolymphoid neoplasms a survey of participants in the college of American pathologists flow cytometry proficiency testing program

Archives of Pathology and Laboratory Medicine

Volumn 139, Issue 10, 2015, Pages 1276-1280

  Keeney, Michael ^a   Halley, Jaimie G ^b   Rhoads, Daniel D ^c   Ansari, M Qasim ^d   Kussick, Steven J ^d,e   Karlon, William J ^f   Mehta, Kumudini U ^g   Dorfman, David M ^h   Linden, Michael A ⁱ  

^a LONDON HEALTH SCIENCES CENTRE   (Canada)

^b Molecular Pathology Division   (United States)

^c UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^d LERNER RESEARCH INSTITUTE   (United States)

^e Phenopath   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g QUEST DIAGNOSTICS NICHOLS INSTITUTE   (United States)

^h BRIGHAM AND WOMEN S HOSPITAL   (United States)

ⁱ UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLOW CYTOMETRY; GOOD LABORATORY PRACTICE; HUMAN; LABORATORY; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MEDICAL SOCIETY; MULTIPLE MYELOMA; NEOPLASM, RESIDUAL; PATHOLOGY; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROCEDURES; QUESTIONNAIRE; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; STANDARDS; UNITED STATES;

FLOW CYTOMETRY; HUMANS; LABORATORIES; LABORATORY PROFICIENCY TESTING; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MULTIPLE MYELOMA; NEOPLASM, RESIDUAL; PATHOLOGY, CLINICAL; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SOCIETIES, MEDICAL; SURVEYS AND QUESTIONNAIRES; UNITED STATES;

EID: 84941296948     PISSN: 00039985     EISSN: 15432165     Source Type: Journal    
DOI: 10.5858/arpa.2014-0543-CP     Document Type: Article

References (30)

1. Craig FE, Foon KA. Flow cytometric immunophenotyping for hematologic neoplasms. Blood. 2008; 111(8): 3941-3967.
2. Campana D, Coustan-Smith E. Detection of minimal residual disease in acute leukemia by flow cytometry. Cytometry. 1999; 38(4): 139-152.
3. van Dongen JJ, Szczepánski T, de Bruijn MA, et al. Detection of minimal residual disease in acute leukemia patients. Cytokines Mol Ther. 1996; 2(2): 121-133.
4. Campana D. Progress of minimal residual disease studies in childhood acute leukemia. Curr Hematol Malig Rep. 2010; 5(3): 169-176.
5. Borowitz MJ, Devidas M, Hunger SP, et al; Children's Oncology Group. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: A Children's Oncology Group study. Blood. 2008; 111(12): 5477-5485.
6. Dworzak MN, Fröschl G, Printz D, et al; Austrian Berlin-Frankfurt-Münster Study Group. Prognostic significance and modalities of flow cytometric minimal residual disease detection in childhood acute lymphoblastic leukemia. Blood. 2002; 99(6): 1952-1958.
7. Griesinger F, Piro-Noack M, Kaib N, et al. Leukaemia-associated immunophenotypes (LAIP) are observed in 90% of adult and childhood acute lymphoblastic leukaemia: detection in remission marrow predicts outcome. Br J Haematol. 1999; 105(1): 241-255.
8. Krampera M, Perbellini O, Vincenzi C, et al. Methodological approach to minimal residual disease detection by flow cytometry in adult B-lineage acute lymphoblastic leukemia. Haematologica. 2006; 91(8): 1109-1112.
9. Neale GA, Coustan-Smith E, Stow P, et al. Comparative analysis of flow cytometry and polymerase chain reaction for the detection of minimal residual disease in childhood acute lymphoblastic leukemia. Leukemia. 2004; 18(5): 934-938.
10. San Miguel JF, Vidriales MB, López-Berges C, et al. Early immunophenotypical evaluation of minimal residual disease in acute myeloid leukemia identifies different patient risk groups and may contribute to postinduction treatment stratification. Blood. 2001; 98(6): 1746-1751.
11. Sievers EL, Lange BJ, Alonzo TA, et al. Immunophenotypic evidence of leukemia after induction therapy predicts relapse: results from a prospective Children's Cancer Group study of 252 patients with acute myeloid leukemia. Blood. 2003; 101(9): 3398-3406.
12. Kern W, Schoch C, Haferlach T, Schnittger S. Monitoring of minimal residual disease in acute myeloid leukemia. Crit Rev Oncol Hematol. 2005; 56(2): 283-309.
13. Walter RB, Buckley SA, Pagel JM, et al. Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remission. Blood. 2013; 122(10): 1813-1821.
14. Terwijn M, van Putten WL, Kelder A, et al. High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON/SAKK AML 42A study. J Clin Oncol. 2013; 31(31): 3889-3897.
15. Rawstron AC, Kennedy B, Evans PA, et al. Quantitation of minimal disease levels in chronic lymphocytic leukemia using a sensitive flow cytometric assay improves the prediction of outcome and can be used to optimize therapy. Blood. 2001; 98(1): 29-35.
16. Böttcher S, Ritgen M, Pott C, et al. Comparative analysis of minimal residual disease detection using four-color flow cytometry, consensus IgH-PCR, and quantitative IgH PCR in CLL after allogeneic and autologous stem cell transplantation. Leukemia. 2004; 18(10): 1637-1645.
17. Moreno C, Villamor N, Colomer D, et al. Clinical significance of minimal residual disease, as assessed by different techniques, after stem cell transplantation for chronic lymphocytic leukemia. Blood. 2006; 107(11): 4563-4569.
18. Rawstron AC, Villamor N, Ritgen M, et al. International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia. Leukemia. 2007; 21(5): 956-964.
19. Böttcher S, Ritgen M, Fischer K, et al. Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: A multivariate analysis from the randomized GCLLSG CLL8 trial. J Clin Oncol. 2012; 30(9): 980-988.
20. Paiva B, Vidriales MB, Cerveró J, et al; GEM (Grupo Español de MM)/ PETHEMA (Programa para el Estudio de la Terapéutica en Hemopatas Malignas) Cooperative Study Groups. Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation. Blood. 2008; 112(10): 4017-4023.
21. Paiva B, Martinez-Lopez J, Vidriales MB, et al. Comparison of immunofixation, serum free light chain, and immunophenotyping for response evaluation and prognostication in multiple myeloma. J Clin Oncol. 2011; 29(12): 1627-1633.
22. Hart AJ, Jagasia MH, Kim AS, Mosse CA, Savani BN, Kassim A. Minimal residual disease in myeloma: Are we there yet? Biol Blood Marrow Transplant. 2012; 18(12): 1790-1799.
23. Gupta R, Bhaskar A, Kumar L, Sharma A, Jain P. Flow cytometric immunophenotyping and minimal residual disease analysis in multiple myeloma. Am J Clin Pathol. 2009; 132(5): 728-732.
24. Mateo G, Montalbán MA, Vidriales MB, et al; PETHEMA Study Group; GEM Study Group. Prognostic value of immunophenotyping in multiple myeloma: A study by the PETHEMA/GEM Cooperative Study Groups on patients uniformly treated with high-dose therapy. J Clin Oncol. 2008; 26(16): 2737-2744.
25. Zhen C, Wang YL. Molecular monitoring of chronic myeloid leukemia: international standardization of BCR-ABL1 quantitation. J Mol Diagn. 2013; 15(5): 556-564.
26. Goldman JM, Gale RP. What does MRD in leukemia really mean? Leukemia. 2014; 28(5): 1131.
27. Flanders A, Stetler-Stevenson M, Landgren O. Minimal residual disease testing in multiple myeloma by flow cytometry: major heterogeneity. Blood. 2013; 122(6): 1088-1089.
28. Wood B, Jevremovic D, Béné MC, et al; ICSH/ICCS Working Group. Validation of cell-based fluorescence assays: Practice guidelines from the ICSH and ICCS, part V: Assay performance criteria. Cytometry B Clin Cytom. 2013; 84(5): 315-323.
29. Hedley BD, Keeney M. Technical issues: flow cytometry and rare event analysis. Int J Lab Hematol. 2013; 35(3): 344-350.
30. Hunger SP, Loh ML, Whitlock JA, et al; COG Acute Lymphoblastic Leukemia Committee. Children's Oncology Group's 2013 blueprint for research: Acute lymphoblastic leukemia. Pediatr Blood Cancer. 2013; 60(6): 957-963.